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Phosphodiesterases (PDEs) hydrolyze the second messengers
cAMP and cGMP. It remains unknown how individual PDE families
selectively recognize cAMP and cGMP. This work reports structural
studies on substrate specificity. The crystal structures of the cata-
lytic domains of the D674A and D564N mutants of PDE10A2 in
complex with cAMP and cGMP reveal that two substrates bind to
the active site with the same syn configuration but different
orientations and interactions. The products AMP and GMP bind
PDE10A2 with the anti configuration and interact with both diva-
lent metals, in contrast to no direct contact of the substrates. The
structures suggest that the syn configurations of cAMP and cGMP
are the genuine substrates for PDE10 and the specificity is achieved
through the different interactions and conformations of the sub-
strates. The PDE10A2 structures also show that the conformation
of the invariant glutamine is locked by two hydrogen bonds and is
unlikely to switch for substrate recognition. Sequence alignment
shows a potential pocket, in which variation of amino acids across
PDE families defines the size and shape of the pocket and thus
determines the substrate specificity.
crystal structure  cyclic nucleotides cAMP and cGMP
Cyclic nucleotide phosphodiesterases (PDEs) are enzymeshydrolyzing the second messengers adenosine and guanosine
3,5-cyclic monophosphates (cAMP and cGMP). The human
genome encodes 21 PDE genes that are categorized into 11
families (1, 2). Selective inhibitors against individual PDE fam-
ilies have been developed as therapeutics for treatment of
various human diseases (3–8). The best known examples are the
PDE5 inhibitors sildenafil (Viagra), vardenafil (Levitra), and
tadalafil (Cialis) that have been used for treatment of male
erectile dysfunction (5). Sildenafil (Revatio) has also been
approved for treatment of pulmonary hypertension (9).
PDE10 was independently identified by three groups in 1999
and shows a dual activity on hydrolysis of both cAMP and cGMP
(10–12). PDE10 is highly expressed in brain striatum (13–16).
Reduction of PDE10A mRNA and protein levels in striatum of
transgenic mice implies a role of PDE10A in Huntington’s
disease (17, 18). Knockout mice experiments suggest that
PDE10A is involved in regulating striatal output, possibly by
reducing the sensitivity of medium spiny neurons to glutama-
tergic excitation (19). The PDE10 inhibitor papaverine is effec-
tive in improving executive function deficits associated with
schizophrenia, and therefore inhibition of PDE10 may represent
an approach to treatment of psychosis (20, 21).
PDE families contain a variable N-terminal regulatory domain
and a conserved C-terminal catalytic domain. Individual PDE
families show different substrate preferences. Crystal structures
have been reported for the catalytic domains of seven PDE
families in the unliganded form or in complex with inhibitors or
products: PDE1B, PDE2A, PDE3B, PDE4B/4D, PDE5A,
PDE7A, and PDE9A (22–34). However, it remains a puzzle how
the conserved catalytic pocket of the PDE families selectively
recognizes cAMP and cGMP. On the basis of the crystal
structures of PDE4-AMP and PDE5-GMP, a ‘‘glutamine
switch’’ mechanism was proposed for the substrate specificity
(31). However, this mechanism is challenged by the mutagenesis
experiments, in which the Q817A mutation in PDE5A1 did not
significantly impact cAMP binding (35).
We have performed a systematic structural study on the substrate
specificity of PDE10A2. Reported here are eight crystal structures
of the catalytic domains of the wild-type PDE10A2 in the unligan-
ded state or complex with products AMP and GMP, the D674A
mutant and its complexes with substrates cAMP and cGMP, and
the D564N mutant and its complex with cAMP. These structures
reveal the conformation and interactions of substrates cAMP and
cGMP in PDE10A2 and suggest a pocket that may determine the
substrate specificity.
Results
Kinetic Properties of the Catalytic Domain of PDE10A2. The catalytic
domain of PDE10A2 (449–789) has a Km and kcat of 56 nM and
0.33 s1 for cAMP and 4.4 M and 1.2 s1 for cGMP. The kcat/Km
values are 5.9 and 0.27 s 1M1, respectively, for cAMP and
cGMP, and the specificity constant (kcat/Km)cAMP/(kcat/Km)cGMP
is 22. These numbers suggest a dual substrate specificity of
PDE10A2, although the enzyme is more effective toward cAMP.
The Vmax values of our PDE10A2 catalytic domain are 507
nmol/min per mg for cAMP and 1,860 nmol/min per mg for
cGMP and are comparable with those for the full-length
PDE10A1 (10). There are two divalent metal ions at the active
site of wild-type PDE10A2. The first ion coordinates with His529,
His563, Asp564, and Asp674, and two waters, and has the same
interactions as zinc in PDE4 (23). The second metal coordinates
with Asp564 and five water molecules.
The D674A mutant lost at least 4 orders of magnitude in the
catalytic activity, as shown by an assay in which no activity was
observed at 40 g/ml D674A mutant, compared with only 5
ng/ml wild-type enzyme required for a normal assay. A conse-
quence of the D674A mutation is loss of zinc ion, as confirmed
by no electron density for the zinc site in the structures of
unliganded D674A, D674A-cAMP, and D674A-cGMP. This
observation implies that zinc is not critical for assembly of the
PDE subdomains (23) but is essential for the catalysis. The
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D564N mutant has the catalytic activity 1/1,000 of the wild-
type PDE10A2, although both divalent metals are found in the
D564N structures.
Architecture of PDE10 Structures. Although the PDE10A2 catalytic
domain with residues 449–789 was used in the crystallization, only
449–770 can be traced unambiguously in the maps. The C-terminal
residues 771–789 in all of the crystals and residues 571–586 of
molecule B in the structures of PDE10A-GMP, D674A-cAMP,
D674A-cGMP, and D564N-cAMP cannot be traced. Three resi-
dues from the expression vector, Ser446, His447, and Met448, have
clear electron density and are included in the structures.
The catalytic domain of PDE10A2 contains 15 -helices and no
-strands (Fig. 1). The topological folding of PDE10A2 is the same
as those of known structures of seven PDE families. The superpo-
sition of the PDE10A2 catalytic domain over the cAMP-specific
PDE4D2 and the cGMP-specific PDE5A1 yielded rmsd values of
1.2 Å for the backbone atoms of 291 comparable PDE4D2 residues
and 1.5 Å for 270 comparable PDE5A1 residues, indicating the
overall similarity. The main difference between PDE10A2 and
PDE4D2 occurs at the N terminus, in which H1 in PDE4D2
becomes a coil in PDE10A2 and H2 in PDE4D2 corresponds to a
310 helix. The short helix H4 in PDE4 is missing in PDE10A2,
probably resulting from the absence of 2 aa. However, PDE10A2
contains an extra helix at the N terminus, which occupies a location
similar to that in PDE5A1 with a positional difference 3 Å. The
H-loop of PDE10A2 (residues 571–592) contains two short
-helices and is comparable with that of PDE4D2 but not PDE5A1,
in which the H-loop has variable conformations (34).
All eight crystal structures have the same space group with
similar cell dimensions (Table 1) and contain two catalytic domains
in their asymmetric units, which are related by a rotation axis of
100°. Because this angle differs from a twofold axis, the associ-
ation of two PDE10A2 molecules appears to be crystallographic
packing but is not biologically relevant. Superposition of molecules
A over B yielded rmsd values of 1.4–1.6 Å for the eight structures,
suggesting conformational changes of some loops. Indeed, residues
689–718 of the M-loop shift their C atoms as much as 7.5 Å,
whereas other portions of the molecule remain comparable. The
movements appear to be forced by the crystal lattice packing, as
shown by the fact that the transposition of molecule A to B results
in a clash with symmetry-related molecules.
No Significant Conformational Changes on Mutation or Substrate
Binding. Structural superposition of the D564N and D674A mutants
over the unliganded PDE10A2 yielded rmsd values of 0.10 and 0.12
Å for the C atoms of molecule A, 0.18 and 0.17 Å for molecule B,
indicating no conformational changes on the mutations. The bind-
ing of cAMP, cGMP, or GMP caused 2.5–4.7% shrinking in the
crystallographic a axis of D674A-cAMP, D564N-cAMP, D674A-
cGMP, and PDE10A2-GMP (Table 1) and disorder of the H-loop
residues 671–685 in molecule B of these structures. However,
superposition of the unliganded PDE10A2 structure over
PDE10A2-AMP, PDE10A2-GMP, D674A-cAMP, D564N-
cAMP, and D674A-cGMP yielded rmsd values of 0.13, 0.24, 0.33,
0.28, and 0.29 for molecule A, and 0.16, 0.28, 0.72, 0.53, and 0.80 for
molecule B, implying overall conformational similarity. A careful
examination showed that residues Lys705–Ile708 of the M-loop shift
as much as 4 times the average rmsd in the five substrate–product
complex structures. These changes appear to be the consequence of
lattice contacts promoted by the hydrogen bond of cAMP/cGMP
with the carbonyl oxygen of Leu706 of a symmetry-related molecule.
In addition, the N-terminal residues 462–470 and 480–482 in
molecule A of D674A-cGMP showed C positional changes 2–4
times the average difference because of the additional binding of
cGMP to the N terminus. The only biologically significant change
is the reorientation of the side chain of Leu635 of molecule A in the
structures of D674A-cAMP and D564N-cAMP to avoid clashing
with the ribose of cAMP.
Different Binding of Substrates cAMP and cGMP. Substrates cAMP
and cGMP bind only at the active site of molecule A but not B of
PDE10A2 (Fig. 2). The failure of substrate binding to B is probably
because of the movement of both helix H14 and the M-loop into the
active site [supporting information (SI) Fig. 5]. For example, Ile692
of H14 is located 4 Å to Phe729 in molecule B and thus blocks the
interactions of the purines of cAMP and cGMP with Phe729 and
Gln726. The cAMP binding in the D674A-cAMP and D564N-
cAMP structures is the same. The adenine of cAMP is sandwiched
by Phe729 on one side and Ile692 and Phe696 on another side. N6 and
N7 of adenine of cAMP form hydrogen bonds with OE1 and NE2
of Gln726, respectively. The cyclic phosphate group of cAMP forms
one hydrogen bond with His525 and three with water molecules. The
ribose O5 of cAMP hydrogen-bonds with a water molecule. O2
forms two hydrogen bonds with a water molecule and the carbonyl
oxygen of Leu706 from symmetry-related molecule B. In addition,
cAMP interacts through van der Waals forces with residues Tyr524,
Leu635, Leu675, Val678, Phe696, and Met713 but does not directly
contact the divalent metals. Substrate cAMP has a syn configura-
tion and a 3 endo ribose.
Three molecules of cGMP bind to the PDE10A2 catalytic
Fig. 1. Structures of the catalytic domain of PDE10A2. (A) Ribbon diagram. Divalent metals zinc and magnesium are shown in red and purple. Green balls–sticks
represent cAMP. (B) Superposition of PDE10 (green ribbons) over PDE4 (gold) and PDE5 (salmon). Cyan ribbons represent comparable regions among three
structures.








domain: one at the active site of molecule A and two in a pocket
formed by the N-terminal residues of molecule A and symmetry-
related molecules. The cGMP binding at the active site resembles
that of cAMP in several aspects (Fig. 2), including the same syn
configuration, shrinkage in a axis of the crystal, disorder of residues
571–586 in molecule B, and a hydrogen bond with the carbonyl
oxygen of Leu706 from a symmetry-related molecule. However,
significant differences between the binding of cAMP and cGMP are
observed. The orientation of cGMP is flipped by 180° from that
of cAMP, whereas their bases and phosphates occupy a similar
location (Fig. 2). As result, the hydrogen bond of His525 with
phosphate O2 of cAMP is swapped to O5 of cGMP, and Gln726
forms only one hydrogen bond to N7 of cGMP.
An unexpected observation is that two molecules of cGMP bind
to the N terminus of molecule A in D674A-cGMP. At this site,
cGMP interacts with Ile450–Ser453 of molecule A, symmetry-related
residues of Leu547, Leu654–Leu656, Gln743–Pro747 of molecule A, and
symmetry-related Leu466–Lys470 of molecule B. The guanines of
two cGMPs stack against one another and form three hydrogen
bonds with Arg467 and Gln743 from symmetry-related molecules.
The phosphate O2 forms two hydrogen bonds with Ser453 and
Leu656. Because this pocket does not exist in the structures in
complex with cAMP, AMP, and GMP, it appears to be an artifact
of the crystal packing. Nevertheless, the additional cGMP binding
may lead to the positional shift of residues 462–471 and 480–483 of
molecule B in D674A-cGMP, which is 2- to 4-fold the overall rmsd.
Table 1. Statistics on diffraction data and structure refinement







Space group P212121 P212121 P212121 P212121 P212121 P212121 P212121 P212121
a, Å 51.1, 51.4 49.8 51.4 49.3 48.7 51.4 49.4
b, Å 82.0 82.0 81.9 82.0 82.3 82.0 82.2 82.3
c, Å 155.4 155.5 156.7 155.4 153.2 154.0 155.2 155.9
Resolution, Å 1.56 1.56 1.90 1.45 1.45 1.52 1.56 1.90
Reflections 85,847 87,893 48,795 110,590 101,420 95,665 91,666 47,078
Redundant 12.0 10.2 6.7 10.1 5.8 9.6 7.4 10.0
Complete, % 91.6 (58.5)* 93.3 (62.1) 94.8 (67.4) 94.4 (71.6) 90.9 (50.0) 99.9 (99.1) 97.0 (77.5) 92.3 (64.2)
Average I/ 9.7 (2.2) 8.2 (2.0) 7.9 (2.0) 8.9 (2.1) 11.1 (2.2) 10.0 (2.5) 12.7 (3.3) 7.7 (2.1)
Rmerge 0.067 (0.47) 0.094 (0.44) 0.071 (0.33) 0.077 (0.39) 0.073 (0.37) 0.082 (0.45) 0.064 (0.28) 0.078 (0.32)
Structure refinement
R factor 0.197 0.200 0.213 0.209 0.218 0.204 0.209 0.217
Rfree 0.223 (10)† 0.222 (10) 0.249 (10) 0.228 (10) 0.236 (10) 0.222 (10) 0.228 (10) 0.253 (10)
Reflections 81,787 83,987 47,053 101,832 96,206 92,068 89,422 45,261
rmsd for
Bond, Å 0.0075 0.0064 0.0054 0.0066 0.0045 0.0063 0.0045 0.0058
Angle 1.3o 1.2o 1.2o 1.3o 1.3o 1.3o 1.1o 1.2o
Average B factor, Å2
Protein 22.9 (5,266)‡ 19.5 (5,285) 27.1 (5,148) 20.6 (5,306) 19.6 (5,176) 19.7 (5,190) 19.9 (5,292) 26.9 (5,182)
Ligand 20.1 (23) 29.2 (24) 16.0 (22) 22.2 (69) 42.6 (22)
Waters 29.6 (425)‡ 26.2 (399) 30.2 (322) 27.3 (425) 24.9 (437) 25.0 (366) 27.9 (458) 29.9 (320)
Zn 21.3 (2)‡ 22.8 (2) 25.8 (2) 26.8 (2) 34.0 (2)
Mg 15.5 (2)‡ 13.8 (2) 24.9 (2) 15.3 (2) 16.0 (2) 15.1 (2) 19.7 (2) 31.2 (2)
*The numbers in parentheses are for the highest resolution shell.
†The percentage of reflections is omitted for calculation of Rfree.
‡The no. of atoms in the crystallographic asymmetric unit.
Fig. 2. Binding of cAMP and cGMP. (A) Interaction of cAMP (golden bonds) with PDE10A2 residues (green bonds) of the D674A mutant. The dotted lines
represent hydrogen bonds. Small isolated red balls are water molecules. (B) Interaction of cGMP (gold) with D674A residues. (C) Superposition of cAMP (gold)
over cGMP (pink). The residues from D674A-cAMP and D674A-cGMP are shown in blue and green, respectively. (D) Hydrogen bonds of Gln726 with Tyr693 and
a water molecule bound to Trp762 and Tyr730.
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Products AMP and GMP Do Not Simulate Substrate Binding. The
products AMP and GMP bind only to the active site of molecule
A but not to molecule B. Both AMP and GMP have the same
interactions and the same anti configuration and 3 endo puck-
ering (Fig. 3). The adenine of AMP and guanine of GMP are
sandwiched by hydrophobic residues Phe729 on one side and
Ile692 and Phe696 on another side. The adenine of AMP forms
two hydrogen bonds with the side chain of Gln726 compared with
only one between GMP and Gln726. The interactions of AMP
with PDE10A2 are the same as those in the structure of
PDE4-AMP, in terms of hydrogen-bonding pattern, nucleotide
conformation, and hydrophobic contact (Fig. 3C).
However, the contact pattern of the products AMP/GMP with
the invariant glutamine is different from those of the substrates
cAMP/cGMP although all of the ligands have the same stacking
against Phe729 (Fig. 3D). The products have the anti configuration
in contrast to syn of the substrates. Gln726 of PDE10A2 forms two
hydrogen bonds with N1 and N6 of AMP and one with N1 of GMP.
However, N6 and N7 of cAMP and N7 of cGMP are involved in
hydrogen bonds with Gln726. In addition, the phosphate groups of
the products coordinate directly with both divalent metals and form
hydrogen bonds with metal-bound residue Asp674 (Fig. 3). In
comparison, the closest distance from the substrate atoms to the
divalent metal ions is 4 Å, indicating no direct interaction.
Discussion
The Binding of cAMP and cGMP Simulates the Catalytic Process.
Because the D674A and D564N mutants are basically inactive, it
needs to be addressed whether the substrate binding in the crystal
structures simulates the enzymatic process. The following obser-
vations suggest that the structural information is biologically rele-
vant. First, the crystals of our PDE10A2 catalytic domain possess
enzymatic activity, as shown by the fact that substrates cAMP and
cGMP were hydrolyzed to AMP and GMP when the unmutated
PDE10A2 crystals were soaked in the substrate solutions. Second,
the wild-type PDE10A2 and the inactive mutants of D674A and
D564N have almost identical conformations for the active-site
residues, implying that substrate binding in the mutants simulates
the biological process. Finally, the same conformation and inter-
actions of cAMP in the mutant structures of D674A-cAMP and
D564N-cAMP suggest that the metal ions do not directly impact the
binding and conformation of the substrates. This hypothesis is
supported by the fact that the closest distance of the substrate atoms
to the metals is 4 Å in the D564N-cAMP structure. Therefore, we
postulate that the substrate conformation and interaction in these
crystal structures resemble those in the catalysis.
It has been reported that cAMP and cGMP exist in equilibrium
between syn and anti configurations in solution, with syn:anti ratios
of 30:70 and 95:5, respectively, for cAMP and cGMP (36). The
(Fo  Fc) and (2Fo  Fc) maps, which were calculated from the
structures before cAMP and cGMP were built in, show only the syn
configuration of cAMP and cGMP bound to the active site of
PDE10A2 (SI Fig. 6). Modeling of anti cAMP and cGMP into the
pocket showed that the phosphate oxygen of the substrates clashes
with two water molecules coordinated with zinc and magnesium,
supporting that the anti conformers do not bind. Thus, the struc-
tures suggest that the syn conformer of cAMP and cGMP is the
biological substrate for PDE10A2. However, it remains unknown
which conformer of cAMP and cGMP is the genuine substrate for
other PDE families. Early studies suggested that the preferable
substrates are: syn cAMP and cGMP for PDE1 and PDE2, anti
cAMP for PDE3 and PDE4, and anti cGMP for PDE3 and PDE5
(37, 38).
Because the substrates and products have different nucleotide
configurations: syn for cAMP and cGMP, and anti for AMP and
GMP, it would be interesting to know whether the enzyme takes an
additional step to perform the syn to anti conversion during
catalysis. To address this question, we carried out an activity assay
in the presence of AMP and observed no significant inhibition by
5 mM AMP. On the basis of such poor binding of AMP, we
hypothesize that the syn products leave the active site right after the
catalysis, and the syn to anti conversion is not catalyzed by the
enzyme but is an automatic process in solution. The occupancy of
the anti AMP and GMP at the active site in the crystals may reflect
the forced binding of the products at high concentration be-
cause they are predominant in solution (39). This argument is
supported by the fact that only the syn configuration of 8-bromo-
AMP was observed in the crystal when its syn configuration is
predominant in solution (24, 39).
Implications for Substrate Specificity. The issue of the substrate
specificity has not been extensively elucidated. The structures of
PDE4D2-AMP, PDE4B2-AMP, and PDE5A1-GMP (24, 28, 31)
show that the side chain of the invariant glutamine is fixed in
opposite orientations in PDE4 and PDE5 and form two hydrogen
bonds with products AMP and GMP. Because chemical formulas
of AMP and GMP differ only in the phosphate portion from cAMP
and cGMP, the conformation and interactions of nucleosides of the
products have been assumed to simulate those of the substrates.
This belief has led to a currently popular model, glutamine switch
for the substrate specificity (31). In this mechanism, the glutamine
is assumed to form two hydrogen bonds with cAMP but one with
cGMP in cAMP-specific PDE families, and similarly cGMP-
specific PDEs would have one hydrogen bond difference for the two
Fig. 3. Binding of products. (A) Interaction of AMP (gold) with PDE10A2 residues (green). (B) Interaction of GMP with PDE10A2 residues. (C) Superposition of
PDE10A2-AMP over PDE4D2-AMP (salmon sticks) (27). (D) Superposition of AMP (pink) over cAMP (gold).








substrates. For PDE families with dual substrate specificity, the side
chain of the invariant glutamine would freely rotate to form two
hydrogen bonds with cAMP or cGMP.
The glutamine switch mechanism is supported by the structure of
dual cAMP/cGMP-specific PDE1B (31), in which the glutamine is
unbonded and could be freely rotated. However, it was challenged
by two lines of evidence. First, the Q817A mutation of PDE5
weakened Km for cGMP by 60-fold but did not significantly change
Km for cAMP (35). Second, the structure of dual-specific PDE2A3
shows that the side chain of Gln859 is fixed by a hydrogen bond with
Tyr827 (22). Thus, for the glutamine to switch, this preexisting
hydrogen bond has to be broken, and the net gain of energy will be
zero.
The glutamine switch is even less likely in view of our PDE10A2
structure, in which the side chain of Gln726 is locked by two
hydrogen bonds with Tyr693 and a water bound to Tyr730 and Trp762
(Fig. 2). In addition, two hydrogen bonds between Gln726 and N6
and N7 of cAMP in the PDE10A2 structure are in a totally different
pattern from the bidentate bonds of N1 and N6 of the model cAMP
predicted by the glutamine switch (31). The single contact between
Gln726 and N7 of cGMP (Fig. 2) differs entirely from the two
predicted hydrogen bonds between the glutamine and N1 and O6
of cGMP (31). Most importantly, different conformations and
interactions between the products and the substrates suggest that
the products are not a reasonable model for the substrate binding,
at least in PDE10, although it is unknown how similar they are in
other PDE families.
The present PDE10A2 structures reveal that cAMP and cGMP
bind to the same pocket but have different orientations and
interactions, suggesting that the substrate specificity is determined
by a different binding of the substrates in the PDE10 family. The
structure-based sequence alignment of the nucleoside-binding
pocket, that we tentatively term ‘‘substrate specificity pocket’’ or
S-pocket, shows dramatic variation of amino acids across PDE
families (Table 2 and Fig. 4). Apparently, the amino acid variation
not only represents changes of the chemical groups in the PDE
families but also defines the shape and size of the binding pocket.
To match the chemical nature and shape of the pocket, substrates
may bind to individual PDE families in the same or different
orientations and configurations with different affinity. In some
extreme cases, poor substrate binding, such as Km  3.9 mM for
cGMP in PDE7 (33) and Km  100 M for cAMP in PDE9 (2),
would explain their preferred cAMP or cGMP specificity. The
invariant glutamine in the S-pocket provides hydrogen bonds for
binding of substrates but may not be a key element in distinguishing
substrates. Instead, multiple elements at the S-pocket must work
together to determine the substrate specificity. Each amino acid in
the S-pocket may contribute to the specificity differently but should
not exclusively dominate the substrate specificity.
Methods
Protein Expression and Purification of PDE10A2. The cDNA of the
catalytic domain of human PDE10A2 (GenBank BAA84467) was
purchased from American Type Culture Collection (Manassas,
VA). The coding region for amino acids 449–789 of PDE10A2 was
amplified by PCR and subcloned into the expression vector
pET15b. The resultant plasmid pET-PDE10 was transferred into
Escherichia coli strain BL21 (CodonPlus) for overexpression. The
E. coli cell carrying pET-PDE10 was grown in 2 YT medium at
37°C to absorption A600  0.7, and then 0.1 mM isopropyl -D-
Table 2. Alignment of amino acids at the substrate-binding pocket
678 685 689 692 693 713 725 726 729 730 762
PDE10A2 V T A I Y M G Q F Y W
PDE1B P H T L M L S Q F I N
PDE2 Q T A I Y M L Q F M W
PDE3 P H T I V F L Q F I W
PDE11 V S A V T F L Q W I W
PDE4 P Y T I M M S Q F I Y
PDE7 P S S V T L I Q F M W
PDE8 P C A I S V S Q F I W
PDE5 I Q A V A M M Q F I W
PDE6 I Q A V A M L Q F I W
PDE9 E A V L L F A Q F I Y
Fig. 4. A potential S-pocket. (A) The PDE10A2 residues (green bonds) are superimposed over the PDE4D2 residues (thinner salmon sticks). (B) Surface
presentation of the S-pocket in PDE10.
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thiogalactopyranoside was added for further growth at 20°C over-
night. The recombinant PDE10 protein was purified on columns of
nickel-nitrilotriacetic acid (Qiagen, Valencia, CA), Q-Sepharose,
and Sephacryl S300 (Amersham Biosciences, Piscataway, NJ). A
typical purification yielded 10 mg of PDE10A2 with a purity
95% from a 2-liter cell culture. The D674A and D564N mutants
were produced by a QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA) and verified by DNA sequencing. Over-
expression and purification of the mutants used the same protocols
for the wild-type protein.
Enzymatic Assay. Enzymatic activity of the catalytic domains of
PDE10A2 and its mutants was assayed by using [3H]cAMP or
[3H]cGMP (20,000 cpm per assay) as substrates in a reaction
mixture of 20 mM TrisHCl, pH 7.5/1.0 mM DTT/10 mM MgCl2 at
room temperature for 15 min (33). The reaction was terminated by
the addition of 0.2 M ZnSO4/Ba(OH)2. Radioactivity of unreacted
[3H]cAMP or [3H]cGMP in the supernatant was measured by a
liquid scintillation counter. The turnover rate was measured at nine
concentrations of substrate and at hydrolysis of 15–50% substrate.
Each measurement was repeated three times. The parameters of
Km, kcat, and Vmax were calculated following steady-state kinetics.
Crystallization and Structure Determination. All crystals were grown
by hanging drop and have the space group P212121 with similar cell
dimensions (Table 1). The unliganded PDE10A2 (449–789) was
crystallized against a well buffer of 0.1 M Hepes, pH 7.5/0.2 M
MgCl2/50 mM 2-mercaptoethanol (2-ME)/16% PEG 3350. Crystals
of the D564N and D674A mutants were grown against a well buffer
of 0.1 M Hepes, pH 7.5/0.1 M MgCl2/100 mM 2-ME/13% PEG
3350. The complexes of PDE10A2-AMP, PDE10A2-AMP,
D674A-cAMP, D674A-cGMP, and D564N-cAMP were prepared
by soaking the unliganded crystals in 20 mM cAMP or 30 mM
cGMP in a buffer of 16% PEG 8000/0.1 M Hepes, pH 7.5/0.1 M
MgCl2/60 mM 2-ME at 4°C for 1.5–6 h. The crystallization buffer
plus 20% ethylene glycol or 15% PEG 400 was used as the
cryosolvent. Diffraction data were collected on beamline X29 at
Brookhaven National Laboratory and processed by program HKL
(Table 1) (40).
The structure of the unliganded PDE10A2 was solved by the
molecular replacement program AMoRe (41), using the PDE4D2
catalytic domain as the initial model. The rotation and translation
searches yielded two solutions that are obviously distinct from
background and have correlation coefficients of 11.2 and 10.4 and
R factors of 0.538 and 0.539 for 4543 reflections between 4 and 8
Å resolution. When the two solutions were added together, the
correlation coefficient and R factor were improved to 0.21 and 0.51.
The electron density map was improved by the density modification
package of CCP4. The atomic model was rebuilt by program O (42)
and refined by program CNS (Table 1) (43). The refined catalytic
domain of the unliganded PDE10A2 was used to solve other
structures.
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